Guanabenz

Guanabenz
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a686003
ATC code	none;
Pharmacokinetic data
Protein binding	90%
Elimination half-life	6 hours
Identifiers
	IUPAC name 2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide;
CAS Number	5051-62-7;
PubChem CID	5702063;
IUPHAR/BPS	5443;
DrugBank	DB00629 ;
ChemSpider	4642445 ;
UNII	GGD30112WC;
KEGG	D04375 ;
ChEMBL	ChEMBL420 ;
CompTox Dashboard (EPA)	DTXSID6045666 ;
ECHA InfoCard	100.023.410
Chemical and physical data
Formula	C8H8Cl2N4
Molar mass	231.08 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1cccc(Cl)c1\C=N\N=C(/N)N;
	InChI InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ ; Key:WDZVGELJXXEGPV-YIXHJXPBSA-N ;
	(verify)

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist of the alpha-2 adrenergic receptor that is used as an antihypertensive drug. It is used to treat high blood pressure (hypertension).^[1]^[2]

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.

References

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.